{
    "clinical_study": {
        "@rank": "129536", 
        "arm_group": {
            "arm_group_label": "avatrombopag", 
            "arm_group_type": "Experimental", 
            "description": "Each subject will receive a single administration during each of the 5 treatment periods as follows: 40 and 60 mg in the fed and fasted state, and 20 mg in the fed state.  Subjects will be randomized to one of four dosing sequences."
        }, 
        "brief_summary": {
            "textblock": "This will be a randomized, open-label, 5-treatment-period study to evaluate the PK and PD of\n      avatrombopag following a single administration of avatrombopag in the fed and fasted\n      condition, or the fed condition, to healthy Japanese and white subjects. A standard\n      high-fat, high calorie breakfast will be used to assess the fed condition."
        }, 
        "brief_title": "A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Thrombocytopenia", 
        "condition_browse": {
            "mesh_term": "Thrombocytopenia"
        }, 
        "detailed_description": {
            "textblock": "The study will comprise a Prerandomization Phase and a Randomization Phase. The\n      Prerandomization Phase will include 2 periods, Screening and Baseline 1. The Screening\n      Period will be up to 3 weeks (21 days) in duration. The Randomization Phase will consist of\n      5 single-dose treatment periods, of which 3 will include administration of avatrombopag in\n      the fed condition and 2 will include administration of avatrombopag in the fasted condition.\n      Each treatment period will be separated by a wash out interval of at least 28 days. Before\n      each treatment period, subjects will complete a baseline period (Baseline Periods 2, 3, 4,\n      and 5), during which baseline assessments will be collected.  A Final Visit will occur 28\n      days (+/- 1 day) after dosing in Treatment Period 5."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          1. Platelet count between the lower limit of normal and 350 x 109/L, inclusive, at\n             Screening and each Baseline; measurements can repeated for verification, if necessary\n\n          2. Nonsmoking, healthy white and Japanese adult male and female subjects, greater than\n             or equal to 20 years and less than or equal to 55 years old at the time of informed\n             consent. (Nonsmokers are defined as those who have discontinued smoking for at least\n             4 weeks before dosing.)\n\n          3. Japanese subjects must be born in Japan of Japanese parents and Japanese\n             grandparents, must have lived no more than 5 years outside of Japan, and must not\n             have changed their lifestyle or habits, including diet, while living outside of\n             Japan.\n\n          4. Body mass index greater than or equal to 18 and less than or equal to 28 kg/m2 at\n             Screening and Baseline Period 1. The BMI in white subjects must be within +/- 2 kg/m2\n             of the BMI in Japanese subjects.\n\n          5. Nonsmoking, healthy  white and Japanese adult males and females between the ages of\n             20 and 55, inclusive\n\n          6. BMI between 18 and 28. inclusive\n\n          7. Females must not be pregnant or lactating, and if they are of childbearing potential\n             they must agree to use a highly effective method of contraception or abstain\n\n          8. Males must have a vasectomy or they and their partner must use a highly effective\n             method of contraception\n\n        Exclusion Criteria\n\n          1. Evidence of organ dysfunction or any clinically significant deviation from normal in\n             their medical history (eg, history of splenectomy); history of arterial or venous\n             thrombosis, including partial or complete thromboses (eg, stroke, transient ischemic\n             attack, myocardial infarction, deep vein thrombosis, pulmonary embolism); known\n             family history of hereditary thrombophilic disorders (eg, Factor V Leiden,\n             antithrombin III deficiency)\n\n          2. Recent clinically significant illness or infection that requires medical treatment\n\n          3. Evidence of disease that may influence the outcome of the study (eg, psychiatric\n             disorders, disorders of the gastrointestinal tract, liver, kidney, respiratory\n             system, endocrine system, hematological system, neurological system, or\n             cardiovascular system), or subjects who have a congenital abnormality in metabolism\n\n          4. Any history of gastrointestinal surgery (eg, hepatectomy, nephrotomy, digestive organ\n             resection)\n\n          5. Any clinically abnormal symptom or organ impairment found by medical history,\n             physical examination, vital sign electrocardiogram (ECG) assessment, or laboratory\n             test results\n\n          6. A known or suspected history of drug or alcohol dependency or abuse or a positive\n             urine drug, cotinine, or alcohol test\n\n          7. Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen\n             (HBsAg), or hepatitis C virus (HCV) antibody at Screening\n\n          8. Weight loss or gain of >10% within 4 weeks before dosing\n\n          9. Known history of clinically significant drug or food allergy\n\n         10. Currently enrolled in another clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02039076", 
            "org_study_id": "E5501-A001-018"
        }, 
        "intervention": {
            "arm_group_label": "avatrombopag", 
            "intervention_name": "avatrombopag", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Glendale", 
                    "country": "United States", 
                    "state": "California"
                }, 
                "name": "Parexel International Early Development Clinical Units"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "last_name": "Eisai Medical Services", 
            "phone": "1-888-422-4743"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The following PK parameters will be estimated for plasma: Cmax, AUC, and t1/2.", 
            "measure": "Pharmacokinetic (PK) profiles of avatrombopag", 
            "safety_issue": "No", 
            "time_frame": "Up to 23 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02039076"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Analyses will carried out for AUEC(0-28d) and Emax using a mixed linear model including fixed terms for dose, race, food, sequence, and period with interaction terms for food by race and for dose by race and subject as random effect.", 
                "measure": "Pharmacodynamic (PD) profiles of avatrombopag", 
                "safety_issue": "No", 
                "time_frame": "Up to 23 Weeks"
            }, 
            {
                "description": "To assess the similarity of the PK and PD of avatrombopag between healthy Japanese and white subjects after a single administration of avatrombopag under fasted conditions", 
                "measure": "Comparison of PK and PD for avatrombopag", 
                "safety_issue": "No", 
                "time_frame": "Up to 23 Weeks"
            }, 
            {
                "description": "Safety assessments include AEs, clinical laboratory results, vital signs, and ECGs.", 
                "measure": "Adverse events (AEs ) as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 23 Weeks"
            }, 
            {
                "description": "Clinical laboratory assessments will include haematology, clinical chemistry, urinalysis and other screening tests", 
                "measure": "Laboratory assessments as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Up to 23 Weeks"
            }, 
            {
                "description": "Vital sign measurements will include systolic and diastolic blood pressure (BP) and pulse rate", 
                "measure": "Vital signs as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Up to 23 Weeks"
            }, 
            {
                "description": "Twelve-lead ECGs will be obtained as a measure of safety and tolerability", 
                "measure": "Electrocardiogram (ECG) as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Up to 23 Weeks"
            }
        ], 
        "source": "Eisai Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eisai Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}